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Background: Bone morphogenetic proteins (BMP) are embryonic morphogens that are aberrantly expressed in
lung cancer. BMPs mediate cell fate decisions and self-renewal of stem cells, through transcription regulation of
inhibitor of differentiation protein/DNA binding proteins (Id1-3). Inhibition of BMP signaling decreases growth and
induces cell death of lung cancer cells lines by downregulating the expression of Id proteins. It is not known
whether the BMP signaling cascade regulates growth and the expression of Id proteins of lung cancer cells
expressing the stem cell markers Oct4 and/or nestin.
Methods: Lung cancer cells expressing Oct4 or nestin were isolated from lung cancer cell lines by stably
transfecting the Oct4 promoter or nestin promoter expression vectors that induce expression of the green
fluorescent protein reporter.
Results: Our studies suggest that lung cancer cells expressing Oct4 or nestin are different cell populations.
Microarray and quantitative RT-PCR demonstrated that the expression of specific stem cell markers were different
between isolated Oct4 and nestin cells. Both the Oct4 and nestin populations were more tumorigenic than controls
but histologically they were quite different. The isolated Oct4 and nestin cells also responded differently to
inhibition of BMP signaling. Blockade of BMP signaling with the BMP receptor antagonist DMH2 caused significant
growth inhibition of both the Oct4 and nestin cell populations but only increased cell death in the nestin
population. DMH2 also induced the expression of nestin in the Oct4 population but not in the nestin cells. We also
show that BMP signaling is an important regulator of Id1 and Id3 in both the Oct4 and nestin cell populations.
Furthermore, we show that NeuN is frequently expressed in NSCLC and provide evidence suggesting that Oct4
cells give rise to cancer cells expressing nestin and/or NeuN.
Conclusion: These studies show that although biologically different, BMP signaling is growth promoting in cancer
cells expressing Oct4 or nestin. Inhibition of BMP signaling decreases expression of Id proteins and suppresses
growth of cancer cells expressing Oct4 or Nestin. Small molecule antagonists of the BMP type I receptors represent
potential novel drugs to target the population of cancer cells expressing stem cell markers.
Keywords: Oct4, Nestin, NueN, BMP, Antagonist, Id1, Id3, Cell growth, Cell death* Correspondence: langenje@rwjms.rutgers.edu
3Division of Thoracic Surgery, Rutgers-Robert Wood Johnson Medical School,
One Robert Wood Johnson Place, P.O. Box 19, New Brunswick, NJ
08903-0019, USA
4Rutgers-Cancer Institute of New Jersey, New Brunswick, NJ 08903-0019, USA
Full list of author information is available at the end of the article
© 2013 Langenfeld et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Langenfeld et al. Molecular Cancer 2013, 12:129 Page 2 of 15
http://www.molecular-cancer.com/content/12/1/129Introduction
Lung cancer is the leading cause of cancer deaths in the
world. More patients die from lung cancer than breast,
colon, prostate, and kidney cancer combined. Approxi-
mately 85% of patients diagnosed with lung cancer will
die from their disease. Lung cancers initially responding
to chemotherapeutic agents will eventually develop re-
sistance to therapy. The expression of stem markers
Oct4 and/or nestin in cancer cells is associated with
resistance to chemotherapeutic agents leading to treat-
ment failures [1-5].
Cancer stem cells (CSC) have been defined as rare
tumor cells with the capacity to self-renewal and initiate
tumor growth in mouse xenografts that histologically re-
capitulate the primary tumor [6,7]. CSC are reported to
be more resistant to chemotherapy agents and the in-
duction of apoptosis compared to other populations of
cells within the same tumor [8-11]. Self-renewal and
chemotherapy resistance in cancer-initiating cells is me-
diate through the expression of inhibitor of differenti-
ation/DNA binding proteins Id1 and Id3 [12-14].
CD44 and CD133 antigens are commonly used to iso-
late CSC from lung and other carcinomas [7,11,15-19].
Isolated CD44 and CD133 cancer cells also express stem
cell regulators Oct4, Sox2, nanog, and nestin [11,20-23].
Oct4 is transiently expressed during early development
in pluripotent stem cells and is required for self-renewal
[24]. Nestin is a marker of neural progenitor cells and is
frequently expressed in cancer cells of non-small cell
lung carcinomas [21,25-27]. Although several studies
have shown CD44 + and CD133 + cells initiate tumor
growth at a significantly lower number of cells compared
to the negative populations, CD44- and CD133- popula-
tions have also been reported be tumor initiating cells in
some studies [17,28]. These studies suggest that further
characterization of specific population of cancer cells
may be needed.
Self-renewal is an essential mechanism required for stem
cells to maintain long-term populating cells. Bone morpho-
genetic proteins 2 and 4 (BMP2/4) mediate self-renewal of
embryonic stems by stimulating the expression of Id1 [29].
BMPs signal through transmembrane serine/kinases com-
posed of type I (alk2, alk3, and alk6) and type II receptors.
The BMP receptor complex phosphorylates smad-1/5,
which then activates response elements on the Id1, Id2, and
Id3 promoters [30,31]. Downregulation of type I BMP re-
ceptors with siRNA and selective small molecule antago-
nists decreases the phosphorylation of smad-1/5 causing a
decrease in expression of Id, Id2, and Id3 in lung cancer cell
lines [32]. The inhibition of BMP type I receptors also in-
duces cell death and causes significant growth inhibition of
lung cancer cell lines, which is mediated through the down-
regulation of Id proteins [32]. The role of the BMP signal-
ing cascade regulating the expression of Id proteins andgrowth of cancer cells expressing Oct4 or nestin is not
known.
We further delineate the heterogeneity of lung cancer
by showing that Oct4, nestin, and Neun are expressed in
lung cancer cell lines and primary lung tumors. We iso-
lated from lung cancer cell lines, cells that express Oct4
or nestin. Our studies suggest that Oct4 and nestin ex-
pressing cancer cells are a different population of tumor-
initiating cells. Inhibition of BMP signaling with the
selective antagonist DMH2 caused a decrease in the
expression of Id1/Id3 and induced significant growth
inhibition of cancer cells expressing Oct4 or nestin.
Blockade of BMP signaling with small molecule antago-
nists of the type I BMP receptors represents a potential
means to regulate the growth of lung cancer cells ex-
pressing stem cell markers.
Materials and methods
Cell culture
The A549 and H1229 lung cancer cell lines were cul-
tured in Dulbecco’s Modified Eagle’s medium (DMEM,
Sigma Aldrich, St Louis, MO, USA) with 5% fetal bovine
serum (FBS) [33]. The lung cancer cell lines H157,
H727, U1752, and H358, and H865 were cultured in
90% RPMI and 10% FCS. The cell lines were obtained
from ATCC and from Malcolm Brock, John Hopkins
University.
Expression vectors
The Oct4 promoter/EGFP plasmid vector was a gift
from Wei Cui (Roslin Institute, Midiothian, UK [34].
The nestin promoter/EGFP was obtained from Rohan
Humphrey (La Jolla, CA). The SM22 promoter/lucifer-
ase expression vector was obtained from Julian Solway
(University of Chicago, Chicago IL) [35]. The SM22 pro-
moter was cloned into the pAcGFP 1–1 expression vec-
tor at the XhoI/Hind III sites (Clontech, Palo Alto, CA).
Cells were transfected using electroporation and then se-
lected with neomycin. Control cells were transfected
with pcDNA 3.1 vector (Invitrogen) expressing EGFP
(Clontech).
Human tumor samples
Human lung tumor tissue samples were obtained from
the Rutgers Cancer Institute of New Jersey (CINJ) after
approval by the institutional review board and ethics
committee of the Rutgers Robert Wood Johnson Med-
ical School. Protocol approval number, 0220013730. The
review committee waived the need for consent since no
patient identifiers were used.
Cell death assay
Cells were plated in 6 well plates at 106 cells per well
and treated with 1 μM DMSO or 1 μM DMH2 for
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and incubated with 0.1 mg/ml of ethidium bromide. Im-
mediately after staining approximately 100 cells were
counted and the percentage of cells that took up eth-
idium bromide was determined.
Cell counts
Cells were plated into 6 well plates at 105 cells per well
and treated with 1 μM DMSO or 1 μM DMH2 for
7 days. The cells were detached with trypsin, stained
with trypan blue, and the number of live cells counted
using a hemacytometer.
Immunoflourescent imaging
Immunofluorescent imaging was performed on both
non-adherent and adherent cells as previously described
[36]. Cells were trypsinized and immunofluorescent im-
aging performed or placed into cloning chambers (Nunc
Lab-Tek, Rochester, NY). Briefly, cells were fixed with
3.7% formaldehyde, permeabilized with 0.5% Triton X,
and blocked with 1% BSA/PBS. Cells were incubated
with primary antibodies in 1X PBS/1% BSA at room
temperature for one hour. Appropriate Alex Fluor 488,
568, or 647 (Invitrogen/Molecular Probes) conjugated
secondary antibodies were used. The secondary antibody
was added for one hour at room temperature. Controls
were treated in the same manner but did not receive
primary antibody. In all negative controls samples there
was no fluorescent signal. Primary antibodies used were
rabbit anti-Oct 4 (Santa Cruz, Santa Cruz, CA), rabbit
anti-human nestin (Chemicon), mouse anti-human
nestin (Chemicon), and mouse anti-NeuN (Chemicon,
Temecula, CA). Fluorescent images were captured
using a Nikon Eclipse TE 300 inverted epifluorescent
microscope and a Cool Snap black and white digital
camera. IP Lab imaging software was used to assign
pseudo-color to each channel.
Immunohistochemistry (IHC)
IHC was performed on formalin-fixed paraffin-embed-
ded primary NSCLC and tumor xenografts in mice.
Antibodies used were mouse anti-Oct4A (Cell Marque,
Rocklin, CA), mouse anti-human nestin (Chemicon),
mouse anti-NeuN (Chemicon, Temecula, CA), and
mouse anti-smooth muscle actin (SMA) (clone 1A4)
(Sigma, St. Louis, MI). IHC was performed on 5 μm
tissue sections. Detection of Oct4 and NeuN on primary
NSCLC used Tris-EDTA antigen retrieval using Vantana
Benchmark XT automated IHC system. Seminoma was
used as a positive control for Oct4 and normal brain for
NeuN. For detection of nestin, NeuN, and SMA antigen
retrieval was performed using Target Retrieval Solution
(Dako Cytomation, Carpentaria, CA). On these samples,
the Biomodule IHC Staining Kit (Invitrogen) was usedas per the manufacture’s instructions. IHC on cell lines
was performed by plating cells on glass cover slips, fix-
ing in 4% paraformaldehyde for 10 minutes, incubating
with primary Oct4 antibody for 1 hour, and using the
biomodule IHC staining kit for detection.
Quantification of gene expression
RNA was extracted using the RNeasy kit as per the manu-
facturer's instructions (Qiagen, Valencia, CA). DNAase was
used to remove any DNA contamination. cDNA was gener-
ated using Advantage RT for PCR kit (BD Biosciences-
Clontech, Palo Alto, CA). Quantitative PCR was performed
with the Stratagene Mx3005p real-time thermal cycler
(Agilent Technologies) with predesigned and validated Taq-
Man gene expression assays according to the manufac-
turer’s specifications (Life Technologies, Grand Island, NY).
Reference numbers used are: GAPDH (Hs99999905_m1),
actin (99999903_m1), ACVRL1 (alk1) (Hs00163543_m1),
ACVR1A (alk2) (Hs00153836_m1), BMR1A (alk3) (Hs0
0831730_s1), BMPR1B (alk6) (Hs00176144_m1), Pou3f1
(Hs00538614_s1) CD133 (Hs01009250_m1), UBE2Q1 (Hs0
1079904_m1), Pank3 (Hs00388176_g1), and Sel1L (Hs0
1071406_m1), Negative control included all reagents except
cDNA. Expression was normalized to GAPDH using the
formula 2Δ CT.
SYBER Green was used to detect double-stranded DNA
for the following primers. Nestin (F) 5′-GCC-CTG-ACC-A
CT-CCA-GTT-TA-3′ (R) 5′-GGA-GTC-CTG-GAT-TTC-
CTT-CC-3′, Sox-2 (F) 5′-CAT-CAC-CCA-CAG-CAA-
ATG-AC-3′ (R) 5′-TGC-AAA-GCT-CCT-ACC-GTA-C
C-3′. Oct4A specific primers were (F) 5′-TCC-CTT-CGC-
AAG-CCC-TCA-T-3′ and (R) 5′-TGA-CGG-TGC-AGG-
GCT-CCG-GGG-AGG-CCC-CAT-C-3′. Oct4 primers
spanning the first intron were (set 2) (F) 5′-GAA-GCT-
GGA-GAA-GGA-GAA-GC- 3′. (R) 5′-GCC-GGT-TAC-
AGA-ACC-ACA-CT-3′. PCR products were run on a
gel, cDNA purified, and sequenced (GENEWIZ, South
Plainfield, NJ). Genomic contamination was examined by
quantitative PCR of RNA samples. Negative control in-
cluded all reagents except cDNA.
Transient gene knockdown
Silencer Select Validated siRNA was used to knockdown
expression of Oct4 (Life Technologies, Grand Island,
NY), ID number S10871. Silencer Select Negative Con-
trol siRNA (4390843) was used to confirm specificity of
knockdown. One million H1299 cells were transfected
with 30 nM siRNA with the Nucleofector II (Amaxa
Biosystems, Gaitherburg, MD) using the manufacture’s
Nucleofector kit T. Optimization was performed using
the enhanced green fluorescent reporter (EGFP) (Clon-
tech) expressed in the pcDNA 3.1 vector (Invitrogen),
which showed approximately 80% of the cells were
transfected using this transfection protocol. Fourty-eight
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sion was examined by quantitative PCR and Western
blot analysis.
Microarray
By FACS, 106 cells expressing high levels of GFP were iso-
lated from H1299 cells stably expressing the Oct4 pro-
moter/GFP or Nestin promoter /GFP reporter vectors.
After 24 hours total RNA was isolated using RNeasy Mini
Kit as described by the manufacturer (Qiagen). DNAse
treated RNA concentration was measured using NanoDrop
1000 spectrophotometer (Thermo Scientific) and the qual-
ity was analyzed with Bioanalyzer 2100 (Agilent). Spotted
microarrays were used to identify differentially expressed
genes between the Oct4/GFP and Nestin/GFP cells. After
reverse transcription with SuperScript II, cDNA was tran-
scribed and the samples were labeled with Cy3, and hybrid-
ized to human one array version 4.2 (HOA 4.2) DNA
microarrays (Phalanx Biotech) containing 30,968 features
probing for approximately 20,230 unique genes, according
to standard procedures followed at the Functional Genom-
ics of the Cancer Institute of New Jersey. Microarrays were
scanned with the GenePix 4000B Scanner (Axon Instru-
ments). The Gene Expression Omnibus (GEO) number for
the microarray data is GSE49281.
Flow cytometry
Flourescence activated cell sorting (FACS) analysis was
performed using a Beckman Coulter Epics XL. Cell sort-
ing was performed using MoFlo XDP cells sorter
(Beckman, Coulter). Cell lines stably transfected with ex-
pression vectors were sorted for cells with high expres-
sion of GFP or no GFP expression. Post sorting FACS
analysis was used to confirm expression. For FACS ana-
lysis, the primary antibody mouse anti-human CD44 (BP
Parmingen, San Diego, CA) was added to cells on ice for
60 minutes. Secondary antibodies were added for 60 mi-
nutes on ice. Control cells were treated with secondary
antibody only.
Isolating cells from tumors
Tumor xenografts from mice were minced and treated
with “digestion buffer” (10 ml HBSS, 50 mg collagenase
powder, 200 μl 2.5% trypsin, 50 μl 1 M CaCl2, 50 μl
DNAse). Fetal bovine serum (FBS) was added and sam-
ples were passed through a 100-micron filter. Cells were
centrifuged and suspended in 3 ml of red blood cell lysis
buffer (0.15 M ammonium chloride, 7 mM potassium
bicarbonate, 0.09 mM tetrasodium EDTA) for 10 mi-
nutes. By FACS, the GFP (+) cells were then isolated.
Western blot analysis
Total cellular protein was prepared using RIPA buffer
containing a protease inhibitor cocktail and proteinconcentration was measured using the BCA assay as
described [37]. In brief, protein was analyzed by SDS-
PAGE, transferred to nitrocellulose (Schleicher and
Schuell, Keene, NH). After blocking, the blots were incu-
bated overnight at 4°C with the appropriate primary
antibody in Tris-buffered saline with 1% Tween (TBST)
and 5% non-fat milk. Secondary antibodies were applied
for 1 hour at room temperature. Specific proteins were
detected using the enhanced chemiluminescence system
(Amersham, Arlington Heights, IL). The primary anti-
bodies that were used were rabbit monoclonal anti-
pSmad 1/5/8 (Cell signaling Technology, Danvers MA)
rabbit anti-actin, an affinity isolated antigen specific anti-
body (Sigma, Saint Louis, MO), rabbit monoclonal anti-
Id1, rabbit monoclonal anti-Id3 (Calbioreagents, San
Mateo, CA), rabbit anti-Oct 4 (Santa Cruz, Santa Cruz,
CA), mouse anti-human nestin (Chemicon), and mouse
anti-NeuN (Chemicon, Temecula, CA).
Differentiation of single cells
By FACS, the GFP (+) and GFP (−) cells were isolated
from Oct4/GFP and Nestin/GFP cell lines and one-
hundred cells placed into cloning chambers containing
cell culture medium (Nunc Lab-Tek, Rochester, NY)
[33]. Cells were cultured in regular culture media for ap-
proximately 14 days until colonies formed. Immuno-
fluorescent imaging was then performed as described
above.
Statistical analysis
To compare two groups, a student t-test was used. Dif-
ferences with P values ≤ .05 were considered statistically
significant.
Results
Expression of Oct4 in lung cancer cell lines
Oct4 has two alternatively spliced variants that code the
Oct4A and Oct4B isoforms. Oct4A regulates self-
renewal of stem cells [38,39] and the function of Oct4B
is not known. To evaluate Oct4A expression in our lung
cancer cell lines, quantitative RT-PCR was performed. A
seminoma (sem), was used as a positive control. A PCR
product was amplified under 34 (29–34) cycles in all cell
lines with no product in the negative control. Sequen-
cing confirmed that the amplified product was Oct4A
and not a pseudogene. To control for the presence of
genomic contamination RNA samples were treated with
DNase and PCR performed. This showed either no
product or amplification at a high cycle number (38–
39 cycles). In addition, to ensure cDNA was being amp-
lified and not genomic DNA, primers recognizing exon
1 and exon 2 were used (primer set 2). Quantitative RT-
PCR amplified the expected 420 base pair product at less
than 34 cycles in all cells lines (Figure 1A).
Figure 1 Oct4A, nestin, and NeuN are expressed in lung cancer cell lines. (A) PCR product of quantitative PCR on lung cancer cell lines
using primer set 2 showing Oct4A expression. (B-a) Western blot analysis using antibody recognizing Oct4A (40 kd). (B-b) Western blot using
only secondary antibody (C) Western blot analysis of Oct4 showing siRNA knockdown of Oct4. (D) Immunoflourscent imaging of H1299 cells
showing nuclear expression of Oct4 (black arrows show positive cells). (E) RT-PCR demonstrating nestin expression in lung cancer cell lines
shown in Figure 1A (lanes 1–6). Lane 8, is actin control, lane 7 negative control. (F) Western blot analysis showing nestin expression in lung
cancer cell lines. (G) Immunoflourscent imaging of H1299 cells showing expression of nestin in cytoplasmic filaments (40x). (H)
Immunoflourescent imaging and corresponding phase contrast image of H1299 cells showing nestin is expressed only in a subset of cells (20x).
White arrows show immunopositive cells. (I) Western blot analysis showing the expression of NeuN in lung cancer cell lines. (J)
Immunoflourescent imaging and corresponding phase contrast image showing nuclear expression of NeuN occurs in a subset of cells (20x).
(K) FACS analysis for CD44 expression on H1299 cells. (a) control cells stained with phycoerythrin (PE) secondary antibody are without
fluorescence. (b) Greater than 99% of cells stained with anti-CD44 and PE secondary demonstrated fluorescence.
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Oct4A, demonstrated bands at 72 kd and 40 kd in the
seminoma and in all 6 lung cancer cell lines examined
(Figure 1Ba). The expected size of Oct4A is approxi-
mately 40 kd. Western blot analysis using only the sec-
ondary antibody revealed a faint band at 72 kd in the
seminoma (Figure 1Bb), suggesting that this could be anon-specific band. Western blot analysis showed that
knockdown of Oct4 using siRNA targeting Oct4A
showed a decrease in the 40 Kd band but not a non-
specific 24 Kd band (Figure 1C). Quantitative PCR also
showed a reduction in the expression of Oct4 following
silencing of Oct4 with siRNA (Additional file 1: Figure
S1). Immunohistochemistry demonstrated that Oct4 is
Figure 2 Immunohistochemical (IHC) staining for Oct4, Nestin,
and NeuN in primary NSCLC. Shown are representative images.
(B, E, G) Negative controls. Positive cells are stained brown. (A)
Seminoma was used as positive control for Oct4. (C) shows nuclear
staining in cancer cells for Oct4 and (D) shows cytoplasmic
expression of Oct4. (F-H) Cancer cells expressing Nestin or NeuN
expression. (aa) Magnified image of cells expressing NeuN. (I-J)
Chromogranin and synaptophysin were not expressed in the NSCLC
shown above.
Langenfeld et al. Molecular Cancer 2013, 12:129 Page 6 of 15
http://www.molecular-cancer.com/content/12/1/129expressed in the nucleus in approximately 16% of the
cells within the cell lines (Figure 1D).
Expression of nestin in lung cancer cell lines
By quantitative RT-PCR, nestin was expressed in all 6
lung cancer cell lines examined (Figure 1E). Amplifica-
tion occurred under 34 cycles (26–34) in all of the cell
lines. Sequencing of the PCR product confirmed that
nestin was amplified. Western blot analysis for nestin
showed strong expression in all the lung cancer cell lines
examined (Figure 1F).
Immunofluorescent imaging of lung cancer cell lines
showed that nestin is expressed in the cytoplasm fila-
ments (Figure 1G). This was confirmed using both
monoclonal and polyclonal anti-human Nestin anti-
bodies. Nestin is expressed only in a subset of the cells
(Figure 1H), which was approximately 20% within each
cell line.
NeuN expression in lung cancer cell lines
Since nestin is a marker of neural cells types, we exam-
ined whether lung cancer cells express NeuN (Neuronal
Nuclei). NeuN is a protein detected in mature neurons
[27]. Monoclonal antibodies detecting NeuN have shown
that NeuN is not expressed in neural progenitors ex-
pressing nestin [40]. Western blot analysis using the
monoclonal NeuN antibody showed an approximately
70 Kd band in all the lung cancer cell lines studied
(Figure 1I). Immunoflourescent imaging showed nuclear
expression of NeuN in the lung cancer cell lines
(Figure 1J). Similar to Oct4 and Nestin expression,
NeuN was expressed in approximately 15% of cells in
each cell line (Figure 1J).
CD44 expression in lung cancer cell lines
By FACS analysis, over 99% of A549 and H1299 cells
expressed CD44 (Figure 1K and data not shown). There-
fore, in A549 and H1299 lung cancer cell lines, CD44
does not appear to represent a specific population of
cells.
Oct4, nestin, and NeuN expression in primary NSCLC
To access whether the heterogeneity identified in the
lung cancer cell lines occurs in primary lung cancer, we
examine by immunohistochemistry (IHC) the expression
of Oct4A, Nestin, and NeuN in NSCLC. Prior studies
have reported that Oct4 and Nestin are expressed in
NSCLC [20,41]. Using a monoclonal antibody recogniz-
ing Oct4A would, we showed nuclear expression of
Oct4A in a seminoma (Figure 2A). Oct4A was expressed
in 11 of the 12 NSCLC examined. Nuclear expression
Oct4A was seen in one NSCLC (Figure 2C) while the
cytoplasmic expression was demonstrated in 10 tumors
(Figure 2D). Cell counts showed only 1-3% of the cancercells expressed Oct4A. Nestin was expressed in frankly
malignant cancer cells in 15 of 20 (75%) NSCLC
(Figure 2F), which is consistent with prior reports [41].
The percentage of cancer cells expressing Nestin was
from < 1% to 3% (Additional file 2: Table S1). Despite
the NSCLC not having morphological features of neuro-
endocrine differentiation, 13 of 18 (72%) NSCLC
expressed NeuN (Figure 2H). The percentage of cells ex-
pressing NeuN was significantly higher than that of Nes-
tin (Additional file 2: Table S1). In comparison, the
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nearly all the cancer cells were immunopositive
(Additional file 2: Table S1). To determine whether
NeuN and/or Nestin immunopositive cells are of neuro-
endocrine or neural lineages, IHC for the neuroendo-
crine marker synaptophysin and chromogranin was
performed. Only 1 of the 10 tumors positive NeuN
and/or Nestin expressed synaptophysin (Figure 2I) and
none expressed chromogranin (Figure 2J). This data sug-
gest that cancer cells expressing NeuN or Nestin are of a
neural lineage.
Isolation of Oct4/GFP and nestin/GFP cells
A549, H1299, and U1752 cell lines were stably trans-
fected with an expression vector containing promoters
of Oct4 or nestin that regulates the expression of GFP.
Human embryonic stem cells expressing this Oct4/GFP
reporter in transgenic mice were shown to be pluripo-
tent [34]. Somatic cells did not activate this exogenous
Oct4 promoter construct [42]. Lung cancer cells ex-
pressing high levels of GFP were obtained in all 3 cell
lines (Figure 3A). The GFP (+) cells were sorted by
FACS and placed into cell culture. After approximately
6 weeks, the percentage of cells expressing GFP de-
creased to approximately 50% and 50% became GFP (−).
By FACS, the GFP (+) and GFP (−) populations were
again isolated to over 99% purity (Figure 3A). Quantita-
tive RT-PCR showed that Oc4 and Sox2 expression was
4 to 5-fold higher in the GFP (+) cells in comparison to
the GFP (−) cells (Figure 3B). Immunofluorescent im-
aging showed that the GFP (+) population expressed
Oct4 (Figure 3C).
All 3 cell lines transfected with the Nestin/GFP reporter
also showed strong GFP expression (Figure 3D). The GFP
positive cells were isolated by FACS and plated into cell
culture. After approximately 4 weeks the GFP + and GFP-
cells were isolated. Quantitative PCR demonstrated a 4.5
fold higher expression of Nestin in the GFP + cells in com-
parison to the GFP (−) cells (Figure 3E). Dual immuno-
fluorscent imaging showed that NeuN was not expressed in
Nestin/GFP cells, suggesting that NeuN and Nestin repre-
sent different cell populations (Figure 3F).
Expression profiles are different between the Oct4/GFP
and Nestin/GFP cells
To examine differences in expression between the Oct4/
GFP and Nestin/GFP cells, the GFP (+) cells were isolated
to over 99% purity by FACS. Quantitative PCR demon-
strated a five-fold higher expression of nestin in the Nestin/
GFP cells compared to Oct4/GFP cells (Figure 3G). There
was two-fold higher expression of Oct4 and CD133 in the
Oct4/GFP cells compared to Nestin/GFP cells (Figure 3G).
Microarray analysis showed that there were 603 genes that
were differently expressed by >2 fold between GFP cellsisolated from the Oct4/GFP and Nestin/GFP cells. By quan-
titative PCR, we examined selected genes that had a 4 fold
or higher difference in expression and were related to can-
cer growth and/or stemness. Pou3f1, which is expressed in
neural progenitors cells [43], was expressed in Nestin/GFP
cells but not Oct4/GFP cells (Figure 3H). Sel1L, regulates
self-fate decisions [44] and enhances tumor progression
[45] was expressed over 3 fold more in Oct4/GFP cells than
the Nestin/GFP cells (Figure 3H). UBE2q1 and Pank3 are
regulators of cellular metabolism and enhance cell growth
[46,47] were also confirmed to have a greater than 3 fold
higher expression in the Oct4/GFP cells compared to Nes-
tin/GFP cells (Figure 3H).
The level of expression of the BMP type I receptors dif-
fers between pluripotent stem cells and stem cell progeni-
tors. Alk3 (BMPRIA) is expressed at much higher level in
pluripotent stem cells compared to Alk6 (BMPRIB) [48].
Alk6 levels increase in some stem cell progenitors. To fur-
ther assess differences between the Oct4/GFP and Nestin/
GFP cells, the level of the BMP type I receptors alk2, alk3,
and alk6 was examined by quantitative RT-PCR. GFP (+)
isolated from Oct4/GFP cells showed a 26 fold higher ex-
pression of alk3 compared GFP (+) cells isolated from Nes-
tin/GFP cells (Figure 3I). Alk2 and alk6 were expressed 2.5
and 5 fold higher respectively in the Oct4/GFP cells com-
pared to the Nestin/GFP cells (Figure 3I).
Oct4/GFP and Nestin/GFP cells are tumor initiating cells
By FACS, the GFP + cells were isolated from the H1299,
A549, and U1752 cells stably expressing the Oct4/GFP or
the Nestin/GFP reporters. Controls were cells stably ex-
pressing GFP by a constitutively active CMV promoter
(Vector/GFP) and Oct4/GFP + cells that lost GFP expres-
sion (GFP -) after isolation. Cell lines were also stably trans-
fected with an expression vector containing the smooth
muscle promoter, Sm22, that drives GFP expression. One
million Sm22/GFP cells did not form tumors in mice after
4 months while 106 Oct4/GFP and Nestin/GFP did
(Figure 4A). One hundred thousand Vector/GFP (0 of 3)
and GFP (−) (0 of 3) from the H1299, A549, and U1759 cell
lines did not form tumors after 4 months, while the Nestin/
GFP cells (3 of 3) and Oct4/GFP (2 of 3) developed tumors
within 2 weeks (Figure 4B-D). One hundred thousand
Sm22/GFP cells from A549 and U1759 cells did not form
tumors after 4 months. In all three cell lines the Nestin/
GFP grew faster than the Oct4/GFP cells.
One hundred thousand Oct4/GFP cells isolated from
the U1752 cells did not initiate tumor growth
(Figure 4D). Tumor initiation was slower in the U1752
cells taking 12 weeks for the Nestin/GFP cells to form a
tumor. When 105 Oct4/GFP cells derived from U1752
cells were co-injected with Matrigel a tumor formed
within 3 weeks while the GFP (−) cells did not develop a
tumor after 4 months. Therefore 3 of 3 Oct4/GFP and
Figure 3 Isolation of lung cancer cells expressing Oct4 or nestin. Lung cancer cell lines were stably expressed with Oct4 or nestin promoters
that drive GFP expression (Oct4/GFP and Nestin/GFP). (A) H1299 cell showing GFP expression after stable transfection with Oct4/GFP reporter. By
FACS, GFP (+) cells were sorted from the Oct4/GFP cells and placed into cell culture. After 6 weeks cells were sorted for the GFP (+) and GFP (−)
populations. (A) FACS analysis shows >99% purity of GFP (+) and GFP (−) cell populations. (B) Quantitative RT-PCR shows significantly higher
expression of Oct4 and Sox2 in GFP (+) cells compared to GFP (−) cells (n = 3). (C) Immunoflourescent imaging showing Oct4/GFP (+) cells stain
for Oct4. (D) The GFP (+) cells were sorted from H1299 cells stably expressing Nestin/GFP reporter and placed into cell culture. After
approximately 8 weeks, the GFP (+) and GFP (−) cells were isolated by FACS. (E) Quantitative RT-PCR shows higher expression of nestin in GFP (+)
cells compared to GFP (−) cells. (F) Dual immunoflourescent image shows NeuN (red) is not expressed in Nestin/GFP (+) (green) cells. (G-I) GFP
(+) cells were isolated from Oct4/GFP and Nestin/GFP cells. Quantitative RT-PCR demonstrates differential expression of stem regulations and BMP
type I receptors between Oct4/GFP and Nestin/GFP cells (n = 2).
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http://www.molecular-cancer.com/content/12/1/129Nestin/GFP cells demonstrated ability to initiate tumor
growth greater than Vector/GFP, Sm22/GFP, and GFP
(−) controls.
Ten Oct4/GFP cells formed tumors compared the 104
Vector/GFP cells (Additional file 3: Table S2). One-
hundred thousand Oct4/GFP and Nestin/GFP cells iso-
lated from the A549 and H1299 cell lines re-established
tumor growth following re-injection into mice (Figure 4F
and data not shown). The Nestin/GFP (+) cells againformed tumors that grew faster than the Oct4/GFP (+)
cells (Figure 4F).
Histologically the Oct4/GFP and nestin/GFP tumors are
different
Hematoxylin and Eosin staining demonstrated that the
Oct4/GFP and Nestin/GFP tumors recapitulated adenocar-
cinomas of the lung but the degree of differentiation was
different. The Oct4/GFP (+) cells isolated from A549 and
Figure 4 Oct4/GFP and Nestin/GFP cells initiate tumor growth. (A-F) Studies show differences in tumor initiation of different cell populations
isolated from H1299, A549, and U1752 cell lines. (A) By FACS, 106 GFP (+) cells were isolated from H1299 cells stably expressing Oct4/GFP, Nestin/
GFP, or SM22/GFP expression vectors and injected subcutaneously into nude mice. (B) 105 GFP (+) cells isolated form Vector/GFP and Oct4/GFP
cells were injected into nude mice. GFP (−) cells were also isolated from Oct4/GFP (+) cells that became GFP (−) after being in cell culture for 6
weeks. (C-D) By FACS, 105 GFP (+) were isolated from A549 and U1752 cells stably expressing Vector/GFP, Oct4/GFP, Nestin/GFP, SM22/GFP
expression vectors and injected subcutaneously into nude mice. GFP (−) cells were isolated from Oct4/GFP cells. (E) 105 GFP (+) and GFP (−) cells
isolated from U1752 Oct4/GFP cells were injected into nude mice with Matrigel. These studies show that Oct4/GFP and Nestin/GFP cells are more
tumorigenic than Vector/GFP, GFP (−), and SM22 cells, which did not form tumors at these cell concentrations. In addition, Nestin/GFP cells grow
faster than Oct4/GFP cells. (F) 104 GFP (+) cells isolated from Oct4/GFP and Nestin/GFP tumors re-established tumor after repeated injections into
nude mice.
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http://www.molecular-cancer.com/content/12/1/129H1299 cells developed tumors that were more differenti-
ated, forming glandular structures resembling acini
(Figure 5A,D). The Nestin/GFP developed poorly differenti-
ated tumors with no gland formation (Figure 5B,E). The
Oct4/GFP tumors also had a large amount of stromal cells
surrounding the acini, which stain for smooth muscle actin
(SMA) demonstrating that they were either smooth muscle
cells or myofibroblasts (Figure 5H). Tumors from the Nes-
tin/GFP cells showed little expression of SMA (Figure 5I).
One million unselected A549 and H1299 cells stably ex-
pressing GFP (Vector/GFP) developed poorly differentiated
tumors with little stromal tissue (Figure 5C, F).BMP signaling in Oct4/GFP and Nestin/GFP cells
The selective antagonist of the type I BMP receptor
DMH2 causes significant growth suppression and a 3-
fold increase in cell death of unselected H1299 and
A549 cells, which involves the downregulation of Id1
and Id3 [32]. To assess whether BMP signaling cascade
is active in cancer cells expressing stem cell markers, the
Oct4/GFP, Nestin/GFP, and GFP (−) cells were treated
with the DMH2. Western blot analysis demonstrated
that DMH2 caused a significant reduction in the expres-
sion of the BMP transcription factor pSmad 1/5 and its
direct downstream targets Id1 and Id3 in Oct4/GFP,
Figure 5 Histologically the tumors formed from Oct4/GFP and Nestin/GFP cells are different. Hematoxilin and Eosin (H & E) staining was
performed on tumors formed from GFP (+) cells isolated from Oct4/GFP and Nestin/GFP of A549 and H1299 cell lines (A-F). Tumors formed from
106 Vector/GFP cells were used as a control. (A,D) Oct4/GFP cells formed more differentiated tumors with acini surrounded by large amounts of
stromal tissue. Black arrows mark stromal tissue. (B,E) The Nestin/GFP and (C,F) Vector/GFP tumors were poorly differentiated with minimal
stromal tissue. (H) IHC show that the stromal tissue found in Oct4/GFP tumors stain for smooth muscle actin (SMA). (I) Very little SMA was
expressed in the Nestn/GFP tumors.
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caused significant growth inhibition of Oct4/GFP, Nes-
tin/GFP, and GFP (−) cells (6B). Inhibition of BMP sig-
naling caused a significantly greater induction of cell
death in the Nestin/GFP cells compared to the Oct4/
GFP (Figure 6C). Since BMP signaling inhibits neural
differentiation of embryonic stem cells [49,50], we exam-
ined whether DMH2 altered the expression of nestin in
Oct4/GFP and/or Nestin/GFP cells. DMH2 induced a
significant increase in the expression of nestin in the
Oct4/GFP cells with a small decrease in expression in
the Nestin/GFP cells (Figure 6D). DMH2 did not cause a
significant change in the expression of Oct4 in either cell
line (data not shown).
Oct4/GFP cells gives rise to cells expressing nestin and
NeuN
The downregulation of Id1 in embryonic stem cells pro-
motes differentiation [29]. The downregulation of Id1
and the induction of nestin in the Oct4/GFP cells fol-
lowing inhibition of BMP signaling suggested that the
Oct4/GFP cells might undergo cellular differentiation.
To assess differentiation, tumors formed from the Oct4/
GFP cells were examined for the expression of nestinand NeuN. By IHC, approximately 3% of the cancer cells
from the Oct4/GFP tumors expressed Nestin and NeuN
(Figure 7). The nestin (+) cells localized to the periphery
of the tumor acini and the NeuN (+) cells were identi-
fied in the center of the acini (Figure 7). Since the nestin
(+) and NeuN (+) cells were identified in two different
regions of the tumor suggests that they are two separate
cell populations.
To further assess differentiation, colonies formed from
a single Oct4/GFP cell were examined for the expression
of nestin or NeuN. By FACS, the GFP (+) and GFP (−)
cells were isolated from the H1299 Oct4/GFP cells and
100 cells plated onto glass cover slips. Microscopy con-
firmed that cells adhered to the cover slips as single
cells. After two weeks colonies were examined by immu-
noflourescent imaging and the percentage of colonies
staining for either NeuN or nestin were determined. The
majority of the cells within each colony lost GFP expres-
sion (Figure 7G). All the colonies from the GFP (+) cells
stained for NeuN and 96% stained for nestin (Figure 7
and Additional file 4: Tables S3 and Additional file 5:
Table S4). The colonies from the GFP (−) cells stained
for NeuN in 52% and nestin in 40% (Additional file 4:
Tables S3 and Additional file 5: Table S4). Dual
Figure 6 Inhibition of BMP signaling decreases Id1 and Id3 expression and inhibits cell growth of Nestin/GFP, Oct4/GFP, and GFP (−)
cells. (A) Western blot analysis of the different cell populations isolated from H1299 cells treated with 1 μM DMH2 for 48 hours. DMH2 decreases
pSmad 1/5 and its transcriptional target Id1 and Id3 in all cell populations. (B) Cells were treated with 1 μM DMH2 for 7 days and live cells
counted. Data represents the mean of 3 independent experiments depicted as percent of vehicle control. (C) Oct4/GFP and Nestin/GFP cells
were treated with 1 μM DMH2 for 48 hours and the percent cells that take up Ethidium bromide counted. Data represents the mean of 4
independent experiments shown as percent of vehicle control. Significant cell death occurred only in the Nestin/GFP cells. (D) Quantitative RT-
PCR for nestin of Oct4/GFP and Nestin/GFP cells treated with 1 μM DMH2 for 48 hours. Data represents the mean of at least 3 independent
experiments. Inhibition of BMP signaling induced nestin expression in Oct4/GFP cells but not Nestin/GFP cells.
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http://www.molecular-cancer.com/content/12/1/129immunoflourescent imaging showed that cells expressing
NeuN or nestin no longer expressed GFP (Figure 7 H-J).
Only small percentage of the cells within each colony
expressed either NeuN or nestin (Figure 7 H-J). Since
only minority of the cells within a colony expressed
NeuN or nestin, suggests that their expression occurs
late in the colony formation. Together, these data sup-
port that Oct4/GFP cells give rise to cells that express
NeuN or Nestin.
Discussion
CD133+ and CD44+ cells are reported to represent
“cancer stem cells” in lung carcinomas, which have also
been shown to express Oct4 and/or nestin [11,20,21].
We provide evidence that lung cancer cells expressing
Oct4 or nestin are different cell populations. The level of
expression of nestin, BMP receptors, and other stem cell
regulators are differentially expressed between the Oct4/GFP and Nestin/GFP cells. We also demonstrate bio-
logical differences between the Oct4/GFP and Nestin/
GFP cells. The Nestin/GFP cells grew faster in nude
mice than Oct4/GFP cells and form poorly differentiated
tumors. The Oct4 cells formed more differentiated tu-
mors and had a much large number of cells expressing
smooth muscle actin. The response to BMP receptor an-
tagonist also differed. DMH2 induced the expression of
nestin in the Oct4/GFP + cells but not in the Nestin/
GFP + cells. Inhibition of the BMP signaling cascade also
caused more cell death in the Nestin/GFP cells com-
pared to the Oct4/GFP cells.
We show that CD44 is expressed in nearly all cancer
cells in our cell lines and CD133 is expressed in both
Oct4 and nestin cell populations. Other reports have
demonstrated that CD133 + cancer cells also express
Oct4, nestin, nanog, and Sox2 [1,51]. The level of ex-
pression of Oct4 and/or nestin in cancer cells may
Figure 7 Oct4/GFP (+) cells give rise to cells expressing nestin and NeuN. 105 GFP (+) cells were isolated from Oct4/GFP cells from A549
and H1299 cells and were injected subcutaneously into nude mice. IHC was performed on the tumors for nestin and NeuN from (A-C) A549
Oct4/GFP and (D-F) H1299 Oct4/GFP cells. (A,D) Represent negative controls. (B,E) Cancer cells expressing nestin (black arrow) were located
along the periphery of the tumor acini (white arrow). (C,F) Cancer cells expressing NeuN (black arrows) were located toward the center of the
tumor acini. (G-J) By FACS, GFP (+) cells were isolated from H1299 Oct4/GFP cells and single cells grown on glass cover slips for 2 weeks.
Immunoflourscent imaging was performed on colonies for expression of GFP, Nestin, or NeuN. Shown are representative images of single
colonies. (G) Immunflourescent image for GFP showing only a portion of cells in the colony express GFP. Arrows show the border of the colony.
(H) Dual immunoflourescent for NeuN (red with white arrows) and GFP (green). (I) Immunoflourescent imaging for nestin (red) and (J) its
corresponding phase contrast image. White arrows show cells expressing nestin.
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http://www.molecular-cancer.com/content/12/1/129induce specific survival mechanisms. Knockdown of nes-
tin with siRNA decreases migration and invasiveness of
pancreatic cancer cell lines [52]. Nestin regulates sur-
vival and self-renewal of neural stem cells [53]. Patients
with NSCLC expressing nestin developed more metasta-
sis and had a poorer survival [41]. Knockdown of Oct4
with siRNA in CD133 + lung cancer cells induced apop-
tosis, decreased tumorigenicity, and increased sensitivity
to chemotherapy and radiation [20]. Our differentiation
assays suggests that Oct4 cells give rise to cancer cells
expressing nestin and NeuN. Further studies are needed
to determine if a hierarchal organization occurs in“cancer stem cells” and examine the biology of other
population of cells found within lung carcinomas.
BMP2 and BMP4 are highly conserved proteins re-
quired for development from insects to humans. BMP
signaling is not active in adult lung tissue but is reacti-
vated with inflammation and cancer [54,55]. BMP2 is
highly overexpressed in 98% of NSCLC with little ex-
pression in paired normal lung tissue and benign lung
tumors [55]. BMP-2 signaling is associated with poor
prognosis and tumor progression [56,57]. BMP signaling
has been shown to stimulate cancer growth, survival, mi-
gration, invasion, metastasis, and tumor angiogenesis of
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pharmacological blockade of BMP type I receptors
causes significant growth inhibition of lung cancer cells
expressing Oct4 or nestin. Inhibition of BMP signaling
also caused significant growth inhibition and of non-
selected cancer cells and GFP (−) cells, which were less
tumorigenic. These data suggest that BMP antagonists
affect the growth of more than just the Oct4 and nestin
populations. Since cancer cells expressing stem cell
makers represent only a small percentage of the cancer
cells, therapeutically targeting the other cell populations
is likely needed.
BMP receptor antagonists mediate growth inhibition
of lung cancer cells by downregulating the expression of
Id proteins [32]. BMP2/4 stimulates self-renewal of em-
bryonic stem cells by inducing the expression of Id1
[29]. Studies have shown that Id1 mediates self-renewal
of “cancer stem cells” and resistance to chemotherapy
[12,13]. Within high grade gliomas, cancer cells with
high Id expression (Id1-high) had a high self-renewal
capacity [12]. Cancer cells with low expression of Id1
(Id1 low) were highly proliferative with little ability to
self-renewal [12]. Inhibition of Id1 in Id1-high cells de-
creased self-renewal capacity and in Id1-low cells it de-
creased proliferation, suggesting that Id proteins have
more than one biological function. Silencing of Id1 and
Id3 together decreased self-renewal and increased sensi-
tivity to chemotherapeutics of colon cancer-initiating
cells [14]. We show that DMH2, a small molecule antag-
onist of the BMP type I receptors, effectively decreases
Id1 and Id3 expression in lung cells expressing stem
cell markers. Future studies are needed to determine
whether BMP antagonists enhance the effectiveness of
chemotherapeutics and decreases self-renewal of cancer
cells expressing stem cell markers.Conclusion
These studies further delineate the heterogeneity of lung
carcinomas. Our studies suggest that cancer cells ex-
pressing the stem cell markers Oct4 and nestin represent
unique cell populations. We show that pharmacological
blockade of the BMP/Id signaling cascade with small
molecules targeting the type I BMP receptors causes sig-
nificant growth inhibition of non-selected and cancer
cells expressing stem cell markers. These studies provide
further evidence that BMP receptor antagonists repre-
sent novel drugs for the treatment of cancer.Additional files
Additional file 1: Figure S1. Quantitative RT-PCR showing siRNA
decreases Oct4 expression in H1299 cells (n = 3).Additional file 2: Table S1. The percentage cancer cells within primary
lung carcinomas expressing nestin, NeuN, or TTF-1 by
immunohistochemistry.
Additional file 3: Table S2. Tumor formation following injection of
injection of 10,000, 100, and 10 cells from GFP (+) cells isolated from
Oct4/GFP and Vector/GFP cells.
Additional file 4: Table S3. By FACS, the GFP (+) and GFP (−) cells
were sorted from H1299 Oct4/GFP cells and plated as single cells onto
glass cover slips. After 2 weeks, colonies were stained for the expression
of nestin and the number of positive colonies counted using
immunoflourescent imaging.
Additional file 5: Table S4. By FACS, the GFP (+) and GFP (−) cells
were sorted from H1299 Oct4/GFP cells and plated as single cells onto
glass cover slips. After 2 weeks, colonies were stained for the expression
of NeuN and the number of positive colonies counted using
immunoflourescent imaging.Competing interests
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